(Q33911859)

30 July 2017

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease (English)

1 reference

30 July 2017

0 references

1

Martin Farlow

1 reference

30 July 2017

Felix Veloso

2

1 reference

30 July 2017

Margaret Moline

3

1 reference

30 July 2017

Jane Yardley

4

1 reference

30 July 2017

Elimor Brand-Schieber

5

1 reference

30 July 2017

Francesco Bibbiani

6

1 reference

30 July 2017

Heng Zou

7

1 reference

30 July 2017

Timothy Hsu

8

1 reference

30 July 2017

Andrew Satlin

9

1 reference

30 July 2017

25 May 2011

1 reference

30 July 2017

1 reference

30 July 2017

11

1 reference

30 July 2017

57

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2377-11-57

30 July 2017

0 references

cites work

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

The tolerability and safety of cholinesterase inhibitors in the treatment of dementia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126705

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-57

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-57

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-57

Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-57

21 January 2018

Identifiers

DOI

10.1186/1471-2377-11-57

1 reference

Dimensions Publication ID

30 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2377-11-57

9 September 2019

1 reference

30 July 2017

1 reference